FOLFOXIRI联合西妥昔单抗或贝伐珠单抗一线治疗BRAFV600E突变转移性结直肠癌:随机II期FIRE-4.5(AIO KRK0116)研究
该随机II期研究纳入107例既往未治疗的BRAFV600E突变转移性结直肠癌患者,按2:1随机接受FOLFOXIRI联合西妥昔单抗(实验组72例)或联合贝伐珠单抗(对照组35例)。主要终点客观缓解率在符合方案人群中实验组为51%(30/59),对照组为67%(20/30)。全分析集中实验组中位无进展生存期显著更短(6.7个月 vs 10.7个月,HR 1.89,P=0.006)。作者认为贝伐珠单抗为基础的化疗仍是BRAFV600E突变转移性结直肠癌患者优选的一线治疗。
要点
- 在符合方案人群中,西妥昔单抗组客观缓解率为51%(30/59),贝伐珠单抗组为67%(20/30)。
- 全分析集中,西妥昔单抗组中位无进展生存期显著短于贝伐珠单抗组(6.7个月 vs 10.7个月,HR 1.89,P=0.006)。
- 作者认为贝伐珠单抗为基础的化疗仍是BRAFV600E突变转移性结直肠癌患者优选的一线治疗。
核心结论
- FOLFOXIRI联合西妥昔单抗与FOLFOXIRI联合贝伐珠单抗相比,在BRAFV600E突变转移性结直肠癌一线治疗中并未诱导更高的客观缓解率。
- 作者认为贝伐珠单抗为基础的化疗仍是BRAFV600E突变转移性结直肠癌患者优选的一线治疗。
研究设计与样本
- 该研究为对照、随机、开放标签II期试验,随机分配109例患者,其中107例纳入全分析集。
- 患者按2:1比例随机接受FOLFOXIRI联合西妥昔单抗(实验组,n=72)或FOLFOXIRI联合贝伐珠单抗(对照组,n=35)。
- 主要终点为按RECIST 1.1评估的客观缓解率,在按方案治疗(ATP)人群中评价。
- 无进展生存期、总生存期、毒性和可行性作为次要终点分析。
主要发现
- 18例患者在首次肿瘤评估前停止研究治疗,ATP人群为89例。
- 在ATP人群中,客观缓解率在西妥昔单抗为基础实验组为51%(30/59),在贝伐珠单抗为基础对照组为67%(20/30)(比值比1.93;80% CI 1.06至3.52;P=0.92[单侧])。
- 在全分析集中,实验组中位无进展生存期显著更差(6.7个月 vs 10.7个月;风险比1.89;P=0.006)。
- 在事件率为64.5%时分析的中位总生存期显示西妥昔单抗治疗患者有更短生存趋势(12.9个月 vs 17.1个月;风险比1.4;P=0.20)。
临床怎么用
- 作者认为贝伐珠单抗为基础的化疗仍是BRAFV600E突变转移性结直肠癌患者优选的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: BRAFV600E mutation is associated with a poor outcome in metastatic colorectal cancer (mCRC). This clinical trial investigated the efficacy of triplet chemotherapy (fluorouracil, folinic acid, oxaliplatin, and irinotecan) combined with either cetuximab or bevacizumab in patients with previously untreated BRAFV600E-mutant mCRC. PATIENTS AND METHODS: In this controlled, randomized, open-label phase II trial, 109 patients were randomly assigned, 107 of whom were included into the full analysis set (FAS). Patients were randomly assigned in a 2:1 ratio to receive either FOLFOXIRI plus cetuximab in the experimental arm (n = 72) or FOLFOXIRI plus bevacizumab in the control arm (n = 35). The primary end point was objective response rate (ORR) according to RECIST 1.1., evaluated in patients treated according to protocol (ATP population). Progression-free survival (PFS), overall survival (OS), toxicity, and feasibility were analyzed as secondary end points. RESULTS: Eighteen patients discontinued study treatment before the first tumor assessment, thus resulting in the ATP population of 89 patients. In these patients, ORR was 51% (30/59) in the cetuximab-based experimental arm and 67% (20/30) in the bevacizumab-based control arm (odds ratio, 1.93; 80% CI, 1.06 to 3.52; P = .92 [one-sided]). In the full analysis set, median PFS was significantly inferior in the experimental arm (6.7 months v 10.7 months; hazard ratio [HR], 1.89; P = .006). Median OS analyzed at an event rate of 64.5% showed a trend toward shorter survival in cetuximab-treated patients (12.9 months v 17.1 months; HR, 1.4; P = .20). CONCLUSION: To our knowledge, FIRE-4.5 is the first prospective and randomized study investigating first-line treatment of BRAFV600E-mutant mCRC. FOLFOXIRI plus cetuximab does not induce a higher ORR when compared with FOLFOXIRI plus bevacizumab in first-line treatment of BRAFV600E-mutant mCRC. Bevacizumab-based chemotherapy remains the preferable first-line treatment of patients with BRAFV600E-mutant mCRC.
引用
- Stintzing S, Heinrich K, Tougeron D, et al. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. J Clin Oncol. 2023. PMID: 37352476. doi:10.1200/JCO.22.01420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。